Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Letters

Latest Letters

Letter
Letter |
15 April 2020
COVID-19
United Kingdom

A letter from civil society to the UK government: Impose access conditions for public funding in COVID-19 research

ip_germany_patentoppositionprotest_peter_bauza_2018_msf243478_3800px
Letter
Letter |
09 April 2020
COVID-19

Letter to governments to revoke WTO ‘opt-out’ on compulsory licences

Open letter: Civil society urges Gilead to take immediate action to ensure access to potential COVID-19 treatment
Letter |
30 March 2020
COVID-19

Open letter: Civil society urges Gilead to take immediate action to ensure access to potential COVID-19 treatment

Letter |
27 March 2020
COVID-19
European Union

Members of European Parliament ask the Commission: Make COVID-19 tools affordable and available

Letter |
25 March 2020
COVID-19

A letter from civil society to the European Commission: Investment in R&D funding for COVID-19 to be conditional on access and affordability for all

People affected with Hepatitis C and HIV protesting at Delhi Patent Office during hearing of Sofosbuvir Patent Opposition, February 2016
Letter
Letter |
25 March 2020
COVID-19

Letter: Gilead must relinquish monopoly on potential coronavirus treatment

Dr Christos Christou commenced his role as International President of Médecins Sans Frontières in the first week of September 2019. Before this, he held a number of roles in the field with MSF and with the Association in MSF Greece. Dr Christou joined MSF in 2002 Photograph by Pierre-Yves Bernard
Letter
Letter |
19 March 2020
COVID-19

COVID-19: A message from MSF International President Dr Christos Christou

5 min
Report cover image
Letter |
06 January 2020
Tuberculosis

Open Letter: Response: Time to Lower the Price of Xpert Cartridges to US$5

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury